Constitutive non-canonical NFκB signaling in pancreatic cancer cells

Cancer Biology and Therapy

Volumn 8, Issue 16, 2009, Pages

  Wharry, Catherine E ^a   Haines, Kathleen M ^a   Carroll, Richard G ^a   May, Michael J ^a,b  

^a UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chemokines; Cytokines; IKK; NF B; NIK; Pancreatic cancer; Signaling

Indexed keywords

B CELL ACTIVATING FACTOR; CXCL13 CHEMOKINE; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; NUCLEAR FACTOR KAPPA B INDUCING KINASE; NUCLEIC ACID BINDING PROTEIN; PROTEIN P100; PROTEIN P52; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR RELB; UNCLASSIFIED DRUG; I KAPPA B KINASE;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; PANCREAS ADENOCARCINOMA; PANCREAS TUMOR; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CELL GROWTH; GENE EXPRESSION REGULATION; GENETICS; HELA CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; METABOLISM; PANCREAS CARCINOMA; PHYSIOLOGY; TUMOR CELL LINE;

CARCINOMA, PANCREATIC DUCTAL; CELL GROWTH PROCESSES; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; I-KAPPA B KINASE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; NF-KAPPA B; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELB;

EID: 85046913982     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.16.8961     Document Type: Article

References (55)

1. Basseres DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006; 25:6817-6830
2. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441:431-436 (Pubitemid 44050137)
3. Gilmore TD, Herscovitch M. Inhibitors of NFkappaB signaling: 785 and counting. Oncogene 2006; 25:6887-6899 (Pubitemid 44657858)
4. Karin M, Yamamoto Y, Wang QM. The IKK NFkappaB system: a treasure trove for drug development. Nat Rev Drug Discov 2004; 3:17-26. (Pubitemid 38088695)
5. Kim HJ, Hawke N, Baldwin AS. NFkappaB and IKK as therapeutic targets in cancer. Cell Death Differ 2006; 13:738-747
6. Bonizzi G, Karin M. The two NFkappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25:280-288 (Pubitemid 38610351)
7. Hayden MS, Ghosh S. Shared principles in NFkappaB signaling. Cell 2008; 132:344-362
8. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE 2006; 2006:13.
9. Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF-induced NEMO-independent processing of NFkappaB2 in maturing B cells. Nat Immunol 2002; 3:958-965 (Pubitemid 35154010)
10. Coope HJ, Atkinson PG, Huhse B, Belich M, Janzen J, Holman MJ, et al. CD40 regulates the processing of NFkappaB2 p100 to p52. EMBO J 2002; 21:5375-5385 (Pubitemid 35231017)
11. Dejardin E, Droin NM, Delhase M, Haas E, Cao Y, Makris C, et al. The lymphotoxinbeta receptor induces different patterns of gene expression via two NFkappaB pathways. Immunity 2002; 17:525-535 (Pubitemid 35223540)
12. Derudder E, Dejardin E, Pritchard LL, Green DR, Korner M, Baud V. RelB/p50 dimers are differentially regulated by tumor necrosis factor-alpha and lymphotoxin-beta receptor activation: critical roles for p100. J Biol Chem 2003; 278:23278-23284 (Pubitemid 36830141)
13. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, et al. Activation by IKKalpha of a second, evolutionary conserved, NFkappaB signaling pathway. Science 2001; 293:1495-1499 (Pubitemid 32801552)
14. Vallabhapurapu S, Matsuzawa A, Zhang W, Tseng PH, Keats JJ, Wang H, et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NFkappaB signaling. Nat Immunol 2008; 9:1364-1370
15. Zarnegar B, Yamazaki S, He JQ, Cheng G. Control of canonical NFkappaB activation through the NIK-IKK complex pathway. Proc Natl Acad Sci USA 2008; 105:3503-3508 (Pubitemid 351723582)
16. Zarnegar BJ, Wang Y, Mahoney DJ, Dempsey PW, Cheung HH, He J, et al. Noncanonical NFkappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat Immunol 2008; 9:1371-1378
17. Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, et al. Frequent engagement of the classical and alternative NFkappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12:115-130 (Pubitemid 47199123)
18. Keats JJ, Fonseca R, Chesi M, Schop R, Baker A, Chng WJ, et al. Promiscuous mutations activate the noncanonical NFkappaB pathway in multiple myeloma. Cancer Cell 2007; 12:131-144 (Pubitemid 47208626)
19. Chandler NM, Canete JJ, Callery MP. Increased expression of NFkappaB subunits in human pancreatic cancer cells. J Surg Res 2004; 118:9-14. (Pubitemid 38490509)
20. Dejardin E, Bonizzi G, Bellahcene A, Castronovo V, Merville MP, Bours V. Highly-expressed p100/p52 (NFKB2) sequesters other NFkappaB-related proteins in the cytoplasm of human breast cancer cells. Oncogene 1995; 11:1835-1841.
21. Dejardin E, Deregowski V, Chapelier M, Jacobs N, Gielen J, Merville MP, et al. Regulation of NFkappaB activity by IkappaB-related proteins in adenocarcinoma cells. Oncogene 1999; 18:2567-2577 (Pubitemid 29216679)
22. Lessard L, Begin LR, Gleave ME, Mes-Masson AM, Saad F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br J Cancer 2005; 93:1019-1023 (Pubitemid 41548396)
23. Lessard L, Saad F, Le Page C, Diallo JS, Peant B, Delvoye N, et al. NFkappaB2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells. Cell Signal 2007; 19:1093-1100 (Pubitemid 46436443)
24. Mishra A, Bharti AC, Varghese P, Saluja D, Das BC. Differential expression and activation of NFkappaB family proteins during oral carcinogenesis: Role of high risk human papillomavirus infection. Int J Cancer 2006; 119:2840-2850 (Pubitemid 44846236)
25. Xu Y, Fang F, St. Clair DK, Sompol P, Josson S, St. Clair WH. SN52, a novel nuclear factor-kappaB inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiation. Mol Cancer Ther 2008; 7:2367-2376
26. Endo T, Nishio M, Enzler T, Cottam HB, Fukuda T, James DF, et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NFkappaB pathway. Blood 2007; 109:703-710 (Pubitemid 46105972)
27. Fujii A, Ohshima K, Hamasaki M, Makimoto Y, Haraoka S, Utsunomiya H, et al. Differential expression of chemokines, chemokine receptors, cytokines and cytokine receptors in diffuse large B cell malignant lymphoma. Int J Oncol 2004; 24:529-538
28. Haiat S, Billard C, Quiney C, Ajchenbaum-Cymbalista F, Kolb JP. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 2006; 118:281-292 (Pubitemid 43911641)
29. He B, Chadburn A, Jou E, Schattner EJ, Knowles DM, Cerutti A. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol 2004; 172:3268-3279 (Pubitemid 38263719)
30. Kryczek I, Lange A, Mottram P, Alvarez X, Cheng P, Hogan M, et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 2005; 65:465-472
31. Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, Rosenbaum JT. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 2003; 101:815-821 (Pubitemid 36139344)
32. Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001; 7:1339-1346 (Pubitemid 34007939)
33. Farrow B, Evers BM. Inflammation and the development of pancreatic cancer. Surg Oncol 2002; 10:153-169
34. Fujioka S, Sclabas GM, Schmidt C, Frederick WA, Dong QG, Abbruzzese JL, et al. Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin Cancer Res 2003; 9:346-354 (Pubitemid 36109751)
35. Fujioka S, Sclabas GM, Schmidt C, Niu J, Frederick WA, Dong QG, et al. Inhibition of constitutive NFkappaB activity by IkappaB alphaM suppresses tumorigenesis. Oncogene 2003; 22:1365-1370 (Pubitemid 36384598)
36. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM. Mitogenic and antiapoptotic role of constitutive NFkappaB/Rel activity in pancreatic cancer. Int J Cancer 2003; 105:735-746 (Pubitemid 36706095)
37. Niu J, Li Z, Peng B, Chiao PJ. Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NFkappaB activation in pancreatic cancer cells. J Biol Chem 2004; 279:16452-16462 (Pubitemid 38509343)
38. Sclabas GM, Fujioka S, Schmidt C, Evans DB, Chiao PJ. NFkappaB in pancreatic cancer. Int J Gastrointest Cancer 2003; 33:15-26.
39. Thomas RP, Farrow BJ, Kim S, May MJ, Hellmich MR, Evers BM. Selective targeting of the nuclear factor-kappaB pathway enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated pancreatic cancer cell death. Surgery 2002; 132:127-134 (Pubitemid 35024752)
40. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappaB RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999; 5:119-127 (Pubitemid 29045184)
41. Wilson W, 3rd, Baldwin AS. Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer. Cancer Res 2008; 68:8156-8163
42. Xiong HQ, Abbruzzese JL, Lin E, Wang L, Zheng L, Xie K. NFkappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. Int J Cancer 2004; 108:181-188 (Pubitemid 37541768)
43. Armstrong T, Packham G, Murphy LB, Bateman AC, Conti JA, Fine DR, et al. Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res 2004; 10:7427-7437 (Pubitemid 39487732)
44. Bertozzi CC, Chang CY, Jairaj S, Shan X, Huang J, Weber BL, et al. Multiple initial culture conditions enhance the establishment of cell lines from primary ovarian cancer specimens. In Vitro Cell Dev Biol Anim 2006; 42:58-62. (Pubitemid 44264507)
45. Madge LA, Kluger MS, Orange JS, May MJ. Lymphotoxin-alpha1 beta2 and LIGHT induce classical and noncanonical NFkappaB-dependent proinflammatory gene expression in vascular endothelial cells. J Immunol 2008; 180:3467-3477
46. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IkappaB kinase that activates the transcription factor NFkappaB. Nature 1997; 388:548-554 (Pubitemid 27339997)
47. Khanbolooki S, Nawrocki ST, Arumugam T, Andtbacka R, Pino MS, Kurzrock R, et al. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. Mol Cancer Ther 2006; 5:2251-2260 (Pubitemid 44530462)
48. Ougolkov AV, Fernandez-Zapico ME, Savoy DN, Urrutia RA, Billadeau DD. Glycogen synthase kinase-3beta participates in nuclear factor kappaB-mediated gene transcription and cell survival in pancreatic cancer cells. Cancer Res 2005; 65:2076-2081
49. Monti P, Marchesi F, Reni M, Mercalli A, Sordi V, Zerbi A, et al. A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. Virchows Arch 2004; 445:236-247 (Pubitemid 39286891)
50. Suto H, Katakai T, Sugai M, Kinashi T, Shimizu A. CXCL13 production by an established lymph node stromal cell line via lymphotoxin-beta receptor engagement involves the cooperation of multiple signaling pathways. Int Immunol 2009; 21:467-476
51. Marchesi F, Monti P, Leone BE, Zerbi A, Vecchi A, Piemonti L, et al. Increased survival, proliferation and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res 2004; 64:8420-8427 (Pubitemid 39491782)
52. Koshiba T, Hosotani R, Miyamoto Y, Ida J, Tsuji S, Nakajima S, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res 2000; 6:3530-3535 (Pubitemid 30694932)
53. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS Jr. Selective activation of NFkappaB subunits in human breast cancer: potential roles for NFkappaB2/p52 and for Bcl-3. Oncogene 2000; 19:1123-1131
54. Packham G. The role of NFkappaB in lymphoid malignancies. Br J Haematol 2008; 143:3-15.
55. 1- to S-phase progression. EMBO J 2006; 25:3801-3812